India's government is promising to vaccinate ทางเข้าxo the entire adult population by the end of 2021.
But questions remain over whether it will have enough doses, and quality issues have emerged at one manufacturing plant.
We've looked at what we know about production capacity in India, and the factors affecting vaccine supplies there.
How much vaccine does India produce now?
The Indian government recently gave out different information for production of the two locally-made vaccines - Covishield and Covaxin - which are the mainstay of the country's vaccine programme.
The Serum Institute of India (SII) makes Covishield (under licence from AstraZeneca), whilst Bharat Biotech makes the locally-developed Covaxin.
On 20 July, the Health Ministry responded to a question in parliament by saying that Covishield production "is planned to be increased" from an estimated 110 million to more than 120 million doses a month.
What other vaccines can India use?
India has approved the Russian-made Sputnik V, and was given three million doses initially.
The plan was to start local production in July or August, but it's now expected that the first batch will be produced in September, going by a recent statement from the Russian side.
The aim is to produce more than 300 million doses of Sputnik a year in India, although when that target might be achieved is not clear.
Novavax, developed in the US and named Covavax in India, is being manufactured by the SII - but has not yet got regulatory approval.
The SII has told the BBC that they are currently stockpiling these vaccine doses.